
Medical Affairs (MA) is increasingly recognised as a strategic and scientific function within the pharmaceutical industry, with responsibilities spanning evidence generation, stakeholder engagement and support for the Quality Use of Medicines (QUM). However, particularly in the Australian context, there is limited empirical evidence examining how MA’s contribution to QUM is understood, articulated and evaluated within pharmaceutical organisations. This study aimed to examine and compare the perceptions of Australian MA and cross-functional (CF) participants regarding MA’s contribution, professional competencies, organisational value and alignment with QUM and business objectives. Semi-structured qualitative interviews were conducted with 21 participants (11 Medical Affairs [MA] and 10 cross-functional [CF] participants) working across MA, regulatory, market access, commercial and sales functions within Australian pharmaceutical companies. Participants were purposively sampled to ensure diversity in role, seniority and organisational context. Interviews were guided by literature on the evolving role of MA and professional capability development. Overall, 35 potential participants were directly invited, of whom 21 participated. Thematic saturation was considered to have been reached at approximately interview 16. Data were analysed using thematic analysis. Among the 11 MA and 10 CF participants, MA participants described their contribution to QUM through scientific education, evidence interpretation, real-world evidence generation and healthcare professional (HCP) and patient engagement. CF participants acknowledged these contributions but highlighted challenges in quantifying MA’s impact using conventional performance metrics. Both groups supported structured competency frameworks, greater recognition of MA’s ethical and scientific stewardship and a shift towards outcome-oriented measures of value. MA is increasingly perceived by participants as an important contributor to QUM through scientific engagement and insight generation. Realising this potential will require improved cross-functional understanding, adaptable competency frameworks and performance metrics aligned with QUM outcomes rather than traditional commercial outputs.
The European Medicines Agency (EMA) PRIority MEdicines (PRIME) scheme supports the development of medicines addressing unmet medical needs through early scientific and regulatory guidance. The aim of this study was to describe the regulatory pathways and pivotal trial characteristics of PRIME-designated medicines that received a positive Committee for Medicinal Products for Human Use (CHMP) opinion between 2018–2024. In this retrospective descriptive analysis, public EMA documents were reviewed. Extracted variables included regulatory characteristics (orphan drugs designation, advanced therapy medicinal products, new active substances, accelerated assessment, conditional marketing authorisation, exceptional circumstances and withdrawals), procedural timelines and pivotal trial features (phase, randomisation, blinding, comparator, number of arms, sample size and objectives). The analysis was conducted in two parts. In the first part, medicine was the unit of analysis to describe characteristics and regulatory pathways. In the second part, the unit of analysis was the medicine-indication pair defined as a unique combination of a medicine and an authorised indication and used to describe the main studies on which the CHMP based its positive opinion. Different indications for the same medicine were analysed separately when supported by distinct evidence packages, whereas indications supported by a common evidence package were analysed jointly to avoid double counting. Categorical variables were expressed as frequencies and proportions. Time intervals were calculated in calendar days and summarised as medians with interquartile range (IQR). Thirty-six PRIME-designated medicines received a positive CHMP opinion between 2018 and 2024. Oncology was the most frequent therapeutic area (12/36, 33.3
Medical Affairs (MA) is the pharmaceutical medicine discipline responsible for medically governed scientific exchange, post-approval evidence generation, and stakeholder engagement. As MA adopts artificial intelligence (AI), governance must keep pace. We propose that AI use be directed by MA accountability and named human medical judgement. The European Union (EU) AI Act’s transparency provisions generally apply from August 2026. Its high-risk requirements apply from 2 December 2027 for Annex III systems and 2 August 2028 for systems classified through Annex I. In this narrative review, we critically examine the emerging evidence base and current regulatory guidance to propose eight hallmarks characterising AI-enabled MA. Four are foundational governance capabilities: scientific and ethical integrity, evidence generation at scale, advanced scientific communications, and global alignment and regulatory adaptation. Four are emerging applications requiring validation: AI-empowered strategic leadership, AI-enhanced stakeholder engagement, field medical excellence, and digital innovation and agentic AI systems. Named human accountability underpins all eight hallmarks. We provide pharmaceutical leaders with author-proposed implementation tools including a maturity assessment model, a mapping of common MA AI use cases to EU AI Act obligations, a medical-legal-regulatory workflow for AI-generated content, and equity-by-design metrics. The framework proposes a governance-first, structured pathway for responsible AI adoption in MA that is designed to preserve scientific integrity.
Advances in analytical characterisation, functional assays, pharmacokinetic evaluation and manufacturing science have enabled regulatory agencies to increasingly rely on the totality of evidence, reducing the need for comparative clinical efficacy trials in scientifically justified circumstances. Consequently, the principal challenge surrounding biosimilars has shifted from demonstrating biosimilarity to ensuring their effective implementation in routine clinical practice. Despite this strong scientific consensus, variability in clinical uptake persists across healthcare systems, limited by professional uncertainty, patient concerns, organisational barriers and inadequate communication. Clinical pharmacists are uniquely positioned to bridge this gap between regulatory science and clinical implementation. This article discusses concrete strategies through which pharmacists translate regulatory confidence into clinical confidence, including interpretation of comparability evidence for prescribers, structured patient counselling to mitigate the nocebo effect and support shared decision-making, coordination of switching and traceability programmes, multidisciplinary education, and pharmacovigilance and real-world evidence generation. Their contributions across hospital, community and ambulatory care settings are explored, together with their strategic role in Pharmacy and Therapeutics Committees, procurement processes and health policy implementation. Beyond facilitating biosimilar adoption, pharmacists contribute to healthcare sustainability by promoting value-based medicine, resilient procurement strategies, responsible resource allocation and environmentally conscious pharmaceutical practices. Future opportunities, including digital pharmacovigilance, artificial intelligence and personalised implementation strategies, are also discussed. Clinical pharmacists should therefore be regarded not only as medicines experts but also as knowledge translators capable of transforming regulatory guidance into patient-centred clinical practice and sustainable healthcare delivery.
Ataxias are a heterogeneous group of rare neurological disorders characterized by progressive impairment of motor coordination and balance, caused by a broad range of genetic, immune-mediated, and degenerative mechanisms. Despite significant advances in molecular diagnostics and disease characterization, effective disease-targeted treatments remain limited, with omaveloxolone currently representing the only approved therapy for Friedreich’s ataxia. In this review, we provide a comprehensive and up-to-date overview of the clinical drug development pipeline for ataxias, based on a systematic analysis of international clinical trial registries up to April 2026. One hundred and fifty-four interventional pharmacological trials investigating 66 therapeutic agents across phases 1–3 were identified. The majority of ongoing clinical efforts focus on symptomatic and supportive therapies, which together constitute more than half of the pipeline and include the most developmentally advanced programs. Neuroprotective therapies represent a substantial portion of trials but have shown mixed efficacy to date. In contrast, disease-targeted approaches, including gene therapies, antisense oligonucleotides, cell-based therapies, and protein replacement strategies, account for a smaller share of the pipeline and remain largely confined to early-phase development. More than half of investigational agents are repurposed compounds, reflecting a pragmatic strategy to accelerate therapeutic progress in rare disorders. Overall, the ataxia therapeutic landscape is expanding but remains fragmented, underscoring the need for improved patient stratification, validated biomarkers, harmonized registries, and international collaboration to enable the successful translation of emerging therapies into clinical practice.